Successful control of Candida auris transmission in a German COVID-19 intensive care unit.
Candida auris
COVID-19
antifungal treatment
infection prevention and control measures
Journal
Mycoses
ISSN: 1439-0507
Titre abrégé: Mycoses
Pays: Germany
ID NLM: 8805008
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
revised:
07
04
2022
received:
22
03
2022
accepted:
09
04
2022
pubmed:
15
4
2022
medline:
3
6
2022
entrez:
14
4
2022
Statut:
ppublish
Résumé
Candida auris a frequently multidrug-resistant yeast species that poses a global health threat due to its high potential for hospital outbreaks. While C. auris has become endemic in parts of Asia and Africa, transmissions have so far rarely been reported in Western Europe except for Great Britain and Spain. We describe the first documented patient-to-patient transmission of C. auris in Germany in a COVID-19 intensive care unit (ICU) and infection control measures implemented to prevent further spread of the pathogen. Identification of C. auris was performed by MALDI-TOF and confirmed by internal transcribed spacer (ITS) sequencing. Antifungal susceptibility testing was carried out. We conducted repeated cross-sectional examinations for the presence of C. auris in the patients of the affected ICU and investigated possible routes of transmission. The index patient had been transferred to Germany from a hospital in Northern Africa and was found to be colonised with C. auris. The contact patient developed C. auris sepsis. Infection prevention and control (IPC) measures included strict isolation of the two C. auris patients and regular screening of non-affected patients. No further case occurred during the subsequent weeks. Reusable blades used in video laryngoscope-guided intubation were considered as the most likely vehicle of transmission. In view of its high risk of transmission, vigilance regarding C. auris colonisation in patients referred from endemic countries is crucial. Strict and immediate IPC measures may have the potential to prevent C. auris outbreaks.
Sections du résumé
BACKGROUND
BACKGROUND
Candida auris a frequently multidrug-resistant yeast species that poses a global health threat due to its high potential for hospital outbreaks. While C. auris has become endemic in parts of Asia and Africa, transmissions have so far rarely been reported in Western Europe except for Great Britain and Spain. We describe the first documented patient-to-patient transmission of C. auris in Germany in a COVID-19 intensive care unit (ICU) and infection control measures implemented to prevent further spread of the pathogen.
METHODS
METHODS
Identification of C. auris was performed by MALDI-TOF and confirmed by internal transcribed spacer (ITS) sequencing. Antifungal susceptibility testing was carried out. We conducted repeated cross-sectional examinations for the presence of C. auris in the patients of the affected ICU and investigated possible routes of transmission.
RESULTS
RESULTS
The index patient had been transferred to Germany from a hospital in Northern Africa and was found to be colonised with C. auris. The contact patient developed C. auris sepsis. Infection prevention and control (IPC) measures included strict isolation of the two C. auris patients and regular screening of non-affected patients. No further case occurred during the subsequent weeks. Reusable blades used in video laryngoscope-guided intubation were considered as the most likely vehicle of transmission.
CONCLUSIONS
CONCLUSIONS
In view of its high risk of transmission, vigilance regarding C. auris colonisation in patients referred from endemic countries is crucial. Strict and immediate IPC measures may have the potential to prevent C. auris outbreaks.
Identifiants
pubmed: 35419847
doi: 10.1111/myc.13443
pmc: PMC9115290
doi:
Substances chimiques
Antifungal Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
643-649Subventions
Organisme : Robert Koch Institute with funds provided by the German Ministry of Health
ID : 1369-240
Informations de copyright
© 2022 The Authors. Mycoses published by Wiley-VCH GmbH.
Références
Euro Surveill. 2018 Mar;23(13):
pubmed: 29616608
N Engl J Med. 2018 Oct 4;379(14):1322-1331
pubmed: 30281988
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012 Oct;55(10):1244-310
pubmed: 23011095
Antimicrob Resist Infect Control. 2022 Jan 21;11(1):12
pubmed: 35063032
Emerg Infect Dis. 2020 May;26(5):876-880
pubmed: 32310077
Antimicrob Resist Infect Control. 2016 Oct 19;5:35
pubmed: 27777756
Emerg Infect Dis. 2020 Nov;26(11):2694-2696
pubmed: 32852265
Enferm Infecc Microbiol Clin (Engl Ed). 2020 Jan;38 Suppl 1:39-44
pubmed: 32111364
J Hosp Infect. 2022 Feb;120:85-89
pubmed: 34785292
Euro Surveill. 2020 Mar;25(12):
pubmed: 32234118
Cochrane Database Syst Rev. 2020 Nov 5;11:CD013779
pubmed: 33150970
MMWR Morb Mortal Wkly Rep. 2021 Jan 15;70(2):56-57
pubmed: 33444298
J Antimicrob Chemother. 2016 Sep;71(9):2569-76
pubmed: 27234462
mBio. 2020 Apr 28;11(2):
pubmed: 32345637
JAC Antimicrob Resist. 2021 Aug 07;3(3):dlab122
pubmed: 34377983
Clin Infect Dis. 2022 Mar 9;74(5):802-811
pubmed: 34145450
PLoS Pathog. 2020 Oct 22;16(10):e1008921
pubmed: 33091071
J Mycol Med. 2018 Sep;28(3):568-573
pubmed: 30030072
Emerg Infect Dis. 2019 Sep;25(9):1763-1765
pubmed: 31223105
J Hosp Infect. 2020 Aug;105(4):648-656
pubmed: 32454076
mSphere. 2017 Dec 13;2(6):
pubmed: 29242834
Infect Control Hosp Epidemiol. 2019 Mar;40(3):380-382
pubmed: 30767810
Mycoses. 2022 Jun;65(6):643-649
pubmed: 35419847
Infect Control Hosp Epidemiol. 2017 Oct;38(10):1240-1243
pubmed: 28793937
Dtsch Arztebl Int. 2019 Apr 19;116(16):271-278
pubmed: 31159914
Mycoses. 2021 Sep;64(9):1062-1072
pubmed: 34009677
Mycoses. 2017 Nov;60(11):758-763
pubmed: 28872735
Emerg Infect Dis. 2019 Sep;25(9):1698-1707
pubmed: 31441749